ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GLMD Galmed Pharmaceuticals Ltd

0.419241
0.00 (0.00%)
Pre Market
Last Updated: 12:00:07
Delayed by 15 minutes
Share Name Share Symbol Market Type
Galmed Pharmaceuticals Ltd NASDAQ:GLMD NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.419241 0.401 0.4216 82 12:00:07

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

17/05/2022 2:09pm

Edgar (US Regulatory)


 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of May 2022

 

001-36345

(Commission File Number)

 

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

 

16 Tiomkin St.

Tel Aviv 6578317, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover

Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by

Regulation S-T Rule 101(b)(7): ☐

 

 

 

 
 

 

Galmed Pharmaceuticals Ltd. (the “Company”) announces that it will hold an Annual General Meeting of Shareholders on Wednesday, June 22, 2022 at 5:00 p.m. (Israel time) at the offices of the Company at 16 Tiomkin St., Tel Aviv, Israel. A copy of the Notice of the Annual General Meeting of Shareholders and Proxy Statement and the Proxy Card are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference.

 

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration No. 333-206292 and 333-227441) and the Company’s Registration Statement on Form F-3 (Registration No. 333-254766).

 

 
 

 

Exhibit Index

 

Exhibit No.   Description
     
99.1   Notice of the Annual General Meeting of Shareholders and Proxy Statement
     
99.2   Proxy Card

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Galmed Pharmaceuticals Ltd.
     
Date: May 17, 2022 By:  /s/ Allen Baharaff
    Allen Baharaff
    President and Chief Executive Officer

 

 

1 Year Galmed Pharmaceuticals Chart

1 Year Galmed Pharmaceuticals Chart

1 Month Galmed Pharmaceuticals Chart

1 Month Galmed Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock